Lymphotoxin expression in human and murine renal allografts by Seeger, Harald et al.
RESEARCH ARTICLE
Lymphotoxin expression in human and
murine renal allografts
Harald Seeger1,2*, Maja T. Lindenmeyer3, Clemens D. Cohen3, Carsten Jaeckel3, Peter
J. Nelson3, Jin Chen1,2, Ilka Edenhofer1,2, Nicolas Kozakowski4, Heinz Regele4,
Georg Boehmig5, Simone Brandt6, Rudolf P. Wuethrich1,2, Mathias Heikenwalder7,
Thomas Fehr8, Stephan Segerer1,2,9
1 Division of Nephrology, University Hospital, Zuerich, Switzerland, 2 Institute of Physiology and Zuerich
Center for Integrative Human Physiology (ZIHP), University of Zurich, Zuerich, Switzerland, 3 Nephrological
Center, Medical Clinic and Policlinic IV, University of Munich, Munich, Germany, 4 Clinical Institute of
Pathology, University of Vienna, Vienna, Austria, 5 Division of Nephrology and Dialysis, Department of
Medicine III, Medical University Vienna, Austria, 6 Institute of Surgical Pathology, University Hospital Zuerich,
Zurich, Switzerland, 7 Division of Chronic Inflammation and Cancer, German Cancer Research Center
(DKFZ), Heidelberg, Germany, 8 Department of Internal Medicine, Kantonsspital Graubuenden, Chur,
Switzerland, 9 Division of Nephrology, Kantonsspital Aarau, Aarau, Switzerland
* harald.seeger@usz.ch
Abstract
The kidney is the most frequently transplanted solid organ. Recruitment of inflammatory
cells, ranging from diffuse to nodular accumulations with defined microarchitecture, is a hall-
mark of acute and chronic renal allograft injury. Lymphotoxins (LTs) mediate the communi-
cation of lymphocytes and stromal cells and play a pivotal role in chronic inflammation and
formation of lymphoid tissue. The aim of this study was to assess the expression of mem-
bers of the LT system in acute rejection (AR) and chronic renal allograft injury such as trans-
plant glomerulopathy (TG) and interstitial fibrosis/tubular atrophy (IFTA). We investigated
differentially regulated components in transcriptomes of human renal allograft biopsies. By
microarray analysis, we found the upregulation of LTβ, LIGHT, HVEM and TNF receptors 1
and 2 in AR and IFTA in human renal allograft biopsies. In addition, there was clear evidence
for the activation of the NFκB pathway, most likely a consequence of LTβ receptor stimula-
tion. In human renal allograft biopsies with transplant glomerulopathy (TG) two distinct tran-
scriptional patterns of LT activation were revealed. By quantitative RT-PCR robust
upregulation of LTα, LTβ and LIGHT was shown in biopsies with borderline lesions and AR.
Immunohistochemistry revealed expression of LTβ in tubular epithelial cells and inflamma-
tory infiltrates in transplant biopsies with AR and IFTA. Finally, activation of LT signaling was
reproduced in a murine model of renal transplantation with AR. In summary, our results indi-
cate a potential role of the LT system in acute renal allograft rejection and chronic transplant
injury. Activation of the LT system in allograft rejection in rodents indicates a species inde-
pendent mechanism. The functional role of the LT system in acute renal allograft rejection
and chronic injury remains to be determined.
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Introduction
Incidence and severity of acute allograft rejection (AR) has been improved with better one-
year graft survival, but long-term allograft outcome has lacked behind expectations [1–5]. A
better understanding of the inflammatory cascade leading to progressive loss of allograft func-
tion will help to define new targets for therapeutic interventions. Cytokines play a significant
role in acute and chronic allograft rejection. Chemokines serve as attractants for immune cells
and lead to their influx from blood into the allograft. Locally, cytokines stimulate immune cell
proliferation, (lymph-) angiogenesis and tissue fibrosis. Conversely, they can exert immune
regulatory functions and limit graft inflammation [4, 6–9]. Whereas AR can be treated success-
fully in the majority of cases, chronic allograft injury such as transplant glomerulopathy (TG)
and interstitial fibrosis/tubular atrophy (IFTA) poses a vast problem. Mechanisms leading to
chronic allograft injury are diverse. Immunological insults such as repeated acute or chronic
cellular or antibody mediated rejection, but also nonimmunological mechanisms such as calci-
neurin inhibitor toxicity, infections (BK nephropathy, pyelonephritis) or postrenal obstruction
might be causative [10]. Even though not considered by the current Banff guidelines, chroni-
cally injured grafts with inflammation in the fibrotic and atrophic areas (i-IFTA) have a signifi-
cantly worse outcome compared to grafts with IFTA alone [11, 12] implicating a deleterious
effect of chronic interstitial inflammation. Lymphotoxins (LTs) are important players in acute
and chronic inflammation, yet their contribution to kidney allograft injury has not been thor-
oughly investigated. LTs are members of the TNF family consisting of the ligands lymphotoxin
α (LTα), β (LTβ), tumor necrosis factor (TNF), and LIGHT (TNSF14). The homotrimer Ltα3
signals via TNF receptors (TNFRs) 1 (and 2) whereas the heterotrimer LTα1β2 only binds to
the lymphotoxin β receptor (LTβR). LIGHT has specificity for the receptors HVEM (Herpes
virus entry mediator), LTβR and DcR3 (reviewed in [13]). LTβR is strongly expressed in the
mouse and human kidney [14, 15] but also by other parenchymal and endothelial cells [16–
19]. Activation via LIGHT or LTα1β2 triggers NF-kB pathways [20]. LT signaling plays a cen-
tral role in chronic inflammation and the formation of tertiary lymphoid organs (TLOs) [21–
23]. In renal allograft biopsies TLOs are present in up to 50% [24]. Even though early studies
have provided evidence for the expression of LTβ in rejected rat and human renal allografts
[25, 26], a comprehensive investigation regarding the expression of LTs in kidney allografts
has not been undertaken. The aim of this study was to examine the differential regulation of
components of the LT system in human renal allograft biopsies and a murine model of renal
transplantation.
Material and methods
In silico analysis of LT expression
In a first analysis, microarray data from the public domain were used (GEO database: http://
www.ncbi.nlm.nih.gov/geo; project GSE9493; Affymetrix HG-U133Plus2.0 arrays). This proj-
ect includes mRNA expression data from human renal biopsies with AR (n = 8), chronic allo-
graft injury (interstitial fibrosis and tubular atrophy, IFTA, n = 21) and controls (n = 12 from
renal cancer nephrectomy samples, nonaffected renal cortex) [27, 28]. We have summarized
clinical characteristics of these patients in Table 1 and S1 Table. CEL file normalization was
performed with the Robust Multichip Average method and the human Entrez-Gene custom
CDF annotation from Brain Array version 15 (http://brainarray.mbni.med.umich.edu/
Brainarray/default.asp) using RMAExpress (Version 1.0.5). We defined a background filter
cut-off using the highest signal value obtained from a nonhuman Affymetrix-control oligonu-
cleotide multiplied by a factor of 1.2, corresponding in the current dataset to a log-based 2
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value of 7.35. Subsequently we analyzed the differential expression with Significance Analysis
of Microarrays (SAM) using TiGR (MeV, Version 4.8.1; http://www.tm4.org/mev/) [29]. The
main results were also confirmed in a single probe analysis approach (ChipInspector, Geno-
matix, Munich, Germany).
Lymphotoxin and related gene expression in renal allografts with
transplant glomerulopathy
For this analysis mRNA from human renal biopsy specimens, collected in an international
multicenter study, the European Renal cDNA Bank-Kro¨ner-Fresenius biopsy bank
(ERCB-KFB, see appendix for participating centers) was used [30]. Biopsies were collected
after informed consent was obtained and with approval of local ethics committees. None of
the transplant donors was from a vulnerable population and all donors or next of kin provided
written informed consent that was freely given. Samples and clinical data were analyzed anon-
ymously. Kidney biopsies of patients with transplant glomerulopathy (TG; n = 14) from the
ERCB-KFB and controls (n = 4; donor kidneys prior to implantation) were microdissected.
mRNA was extracted from the glomerular and the tubular compartment as per standard pro-
tocols, hybridized to HG-U 133 Plus 2.0 cDNA microarrays (Affymetrix) and the intensities
measured as per standard protocols. We carried out quality control and clustering analyses
using the MADMAX (Management and Analysis Database for Multi-platform microArray
eXperiments) platform (https://madmax.bioinformatics.nl, University of Wageningen). This
lead to a distinct separation of the TG samples into two clusters. The same platform was used
to normalize the data using the RMA algorithm [31]. Normalized intensities for each gene
were then expressed as a fraction of the maximum intensity for each gene (i.e. setting the high-
est expression value to 1). Heatmaps were drawn using Multi experiment Viewer 4.8.1 (http://
www.tm4.org/mev/) applying the Pearson clustering strategy. Table 2 and S2 Table display the
basic clinical parameters of the patients with transplant glomerulopathy included in the micro-
array analysis.
Quantitative real-time RT-PCR (qPCR)
For mRNA expression analysis by RT-PCR renal biopsy specimens from ERCB-KFB [30] were
used (see above). Tissue was transferred to RNase inhibitor immediately after the biopsy was
taken. Total RNA was isolated according to a protocol previously reported [30]. Pre-developed
TaqMan reagents were used for human LTα (Hs00236874_m1), LTβ (Hs00242739_m1), LTβ-
Table 1. Basic clinical parameters of the patients included from the public domain (GEO database) for analysis of lymphotoxin expression in the transcriptome of
graft biopsies. (n = number, m = male, f = female, nd = not determined).
Diagnosis n Gender (m/f) Mean age in years (range) Creatinine in μmol/l (range)
Acute rejection 8 6/2 44 (22–54) 253 (161–466)
IFTA 21 15/6 48.6 (24–67) 287 (110–1000)
Controls 12 9/2/nd 55.8 (17–82) 85 (36–114)
https://doi.org/10.1371/journal.pone.0189396.t001
Table 2. Basic clinical parameters of the patients with transplant glomerulopathy included in the microarray analysis. (n = number, m = male, f = female, nd = not
determined, TG = transplant glomerulopathy).
Diagnosis n Mean age in years (range) Recipient sex Creatinine in μmol/l (range) Proteinuria in g/day (range)
TG n 48 (37–68) m/f/nd 6/4/4 256 (143–512) 3.3 (0,0–7.6)
Controls 14 48 (25–61) m/f 0/4 nd nd
https://doi.org/10.1371/journal.pone.0189396.t002
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receptor (Hs00158922_m1), LIGHT (Hs00542477_m1), DcR3 (Hs00187070_m1) and HVEM
(Hs00998604_m1) and the housekeeper genes GAPDH and 18SrRNA (Applied Biosystems,
Darmstadt, Germany). mRNA expression was analyzed by standard curve quantification.
Included in the study were biopsies with borderline lesions (n = 10), AR (n = 22), and signs of
chronic injury (IFTA, n = 7). Control biopsies were taken from living donors before implanta-
tion (n = 10). Clinical data of these patients is summarized in Table 3 and S3 Table.
For the correlation between histopathological changes and the mRNA expression levels of
cytokines and receptors two observers (S.B. and H.S.) blinded to the histological diagnosis of
the initial evaluation reviewed the original biopsy reports of the 39 patients. The histology
slides were not available for direct review. We extracted the following histopathological charac-
teristics: atii = acute tubulointerstitial inflammation (interstitial mononuclear infiltration and
tubulitis), ctii chronic tubulointerstitial inflammation (interstitial fibrosis and tubular atro-
phy), ag = acute glomerulitis, cg = chronic glomerulitis (transplant glomerulopathy),
av = acute intimal arteritis, cv = chronic intimal arteritis (arterial fibrous intimal thickening),
mm = mesangial matrix increase. We also tried to extract information about peritubular capil-
laritis, however this parameter was not mentioned in most of the reports. Thus, we omitted it
from the analysis. In addition, we could not extract sufficient information about C4d peritubu-
lar capillary staining, arteriolar hyalinosis and peritubular capillary basement membrane mul-
tilayering. We scored a 0 if the report said “none”, “discrete”, “minimal” or “isolated”. We
scored a 1 if the report said “low” or “moderate” and a 2 if the report said “strong” or “mas-
sive”. The interobserver correlation was excellent (Spearman’s r between 0.954–1). For correla-
tion between the mRNA expression level and a histopathological change, we used Spearman
rank correlation analysis.
Immunohistochemical localization of LTβ in human renal allograft
biopsies
We performed immunohistochemistry as previously described [15, 32]. In brief, sections were
dewaxed in xylene, rehydrated in a graded series of ethanol, and incubated in 3% hydrogen
peroxide. Avidin (Vector, Burlingame, CA) was used to block endogenous biotin. Autoclaving
was used for heat based antigen retrieval in antigen retrieval solution (Vector). The primary
reagent used was a mouse monoclonal antibody against human LTβ (Clone: B-27 gift from
Biogen, Cambridge, MA, USA) in a 1: 500 dilution. Incubation with primary antibody was per-
formed overnight. Incubation with biotinylated secondary antibody (Vector) for 30 minutes
was followed by ABC reagent (Vector). 3’3’Diaminobenzidine (DAB, Sigma, Taufkirchen,
Germany) with metal enhancement was used as a detection system. A weak methyl green
counterstain of the nuclei was used.
Staining was performed on biopsies from 39 kidney transplants with a histologic diagnosis
of acute cellular rejection (n = 14), acute humoral rejection (n = 6), mixed acute cellular and
humoral rejection (n = 5) and (n = 4) with IFTA. Ten biopsies were implant biopsies which all
showed normal histology except for one biopsy with mild interstitial fibrosis/tubular atrophy.
Semiquantitative evaluation was performed in a blinded fashion. Slides were scored 0 = (no
Table 3. Basic clinical parameters of the patients included from the ERCB-KFB cohort for RTPCR expression analysis. (n = number, m = male, f = female, nd = not
determined, AR = acute rejection, IFTA = interstitial fibrosis and tubular atrophy, Pre-Tx = pretransplant).
Diagnosis n Sex (m/f) Mean age in years (range) Time after transplantation in months (range) Creatinine in μmol/l (range)
Borderline 10 7/3 40 (25–66) 3.8 (0–24) 332.8 (136–919)
AR 22 16/6 52 (38–71) 5.3 (0–48) 217 (177–909)
IFTA 7 4/1/3 nd 52 (42–71) 73.5 (12–180) 294 (120–548)
Pre-Tx 10 5/4/1 nd 48 (27–70) - <97
https://doi.org/10.1371/journal.pone.0189396.t003
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staining), 1 (positive cells present), 2 (numerous positive cells). Since LTβ expression was only
observed in tubular epithelial cells, diffusely infiltrating inflammatory cells and inflammatory
cells in follicular infiltrates, these three parameters were quantified. Table 4 and S4 Table dis-
play the basic clinical parameters of the patients, which were included in the histological analy-
sis. Retrospective analysis of the transplant biopsies was approved by the ethics committee of
the University of Vienna, Austria (permit number 1391/2012).
Mouse experiments
Renal allografts. All animal experiments were performed according to protocols
approved by the legal authorities (Veterinary Office of the Canton of Zuerich; permit number
4888). Mice were housed in specific pathogen-free conditions at the University of Zurich. Kid-
neys from C57/Bl6 mice were transplanted either into CBA mice (fully MHC mismatched allo-
graft) or into C57/Bl6 mice (isograft controls). Mouse renal allografting was performed as
previously described in detail [33]. Surgery was conducted under isoflurane inhalation anes-
thesia, and all efforts were made to minimize suffering of animals. Mice were euthanized by
CO2 inhalation.
Routine renal evaluation. Kidneys were fixed in 10% buffered formalin overnight and
embedded in paraffin following routine protocols. Paraffin blocks were cut at 3 μm and stained
with Haematoxylin-Eosin (H.E.), Periodic Acid Schiff (PAS), and modified Yajima’s Methena-
mine Silver stain [34].
Quantitative RT-PCR. Mouse kidney tissue was immediately transferred to RNAse
inhibitor (RNA later) after euthanization and RNA extracted using standard protocols.
qRT-PCR was performed as described above using pre-developed TaqMan-assays for mLtα
(Mm00440228_gH), mLtβ (Mm00434774_g1), mLtβR (Mm00440228_gH), mTNFRSF14
(HVEM, Mm00619239_m1), mTNFSF14 (LIGHT, Mm00444567_m1) and the housekeeper
genes murine β-actin and 18SrRNA (Applied Biosystems, Darmstadt, Germany). mRNA
expression was analyzed by the delta delta Ct method.
Statistics
Data are given as mean ± SEM. Statistical analysis was performed using Kruskal-Wallis and
Mann-Whitney U tests (IBM SPSS Statistics 20.0, IBM, Armonk, NY and GraphPad Prism
version 5.0 for Windows, GraphPad Software, La Jolla California USA). For correlation analy-
sis, we used Spearman rank correlation. We considered P-values less than 0.05 to indicate sta-
tistically significant differences.
Results
cDNA microarray analysis of lymphotoxin expression in human renal
allograft biopsies with acute and chronic injury
To evaluate LT expression in human kidney allografts, we analyzed transcriptome data from
41 human renal allograft biopsies with AR (AR, n = 8), chronic allograft injury (interstitial
Table 4. Basic clinical parameters of patients from which allograft biopsies were stained for LTβ. (n = number, m = male, f = female, nd = not determined,
AR = acute rejection, IFTA = interstitial fibrosis and tubular atrophy).
Diagnosis n Mean age in years (range) Recipient sex Time after transplantation in months (range)
Control 10 38 (4–65) m/f: 7/3 0,0 (0.0–0.0)
IFTA 4 45 (20–77) m/f: 2/2 46.9 (6.2–126.3)
AR 25 49 (20–69) m/f/nd: 14/10/1 16.0 (0.2–83.2)
https://doi.org/10.1371/journal.pone.0189396.t004
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fibrosis and tubular atrophy, IFTA, n = 21) and nephrectomy controls without rejection
(n = 12). Study subjects were predominantly male and the average age at time of biopsy was 44
years in patients with AR, 48 in patients with IFTA and 56 years in control subjects (Table 1
and S1–S3 Tables). In AR and IFTA, LTβ mRNA was significantly upregulated, as was LIGHT
and its receptor HVEM (Fig 1A and 1B). The ligands LTα and TNF, as well as LTβR mRNA
were expressed, but did not demonstrate a significant induction or downregulation (not illus-
trated). Yet, expression of TNF receptor 1 and 2 mRNAs (the receptor for LTα3) were
increased significantly (Fig 1A and 1B). In addition to transcripts regulated by the canonical
NF-kB pathway known targets of the alternate LTβR signaling pathway, such as CXCL12
(SDF-1α), CXCL13 (BLC), CCL19 (ELC) and BAFF were strongly upregulated (Fig 1C and
1D).
Lymphotoxin mRNA expression patterns in human renal allografts with
transplant glomerulopathy
Transplant glomerulopathy is a pattern of chronic kidney allograft injury, which is linked to a
poor transplant outcome. Recently it has been associated with chronic antibody mediated
rejection, however, also non–immunological causes have been discussed [10, 35]. Clustering
analysis of transcriptional data from the tubulointerstitial compartment resulted in two dis-
tinct expression patterns of lymphotoxins and related genes in patients with transplant glo-
merulopathy. One cluster was characterized by strong upregulation of LTα, TNF, LIGHT,
HVEM, BTLA, CXCL13, CCR7 and CCL21 (Cluster 1), whereas the second pattern was dis-
tinctive by its robust expression of the LTβR, LTβ, TNF receptors 1 and 2, MADCAM and
TROY (Cluster 2) (Fig 2). The clusters persisted when we used mRNA from the (laser dis-
sected) glomerular compartment.
mRNAs of the lymphotoxin family are upregulated/differentially expressed
in human renal allografts with AR and IFTA
To confirm the transcription of components of the LT family in human renal allografts, we
quantified mRNA expression by real-time RT-PCR in another series of 49 allograft biopsies.
These included biopsies with borderline lesions (BR) (n = 10), AR (n = 22), and IFTA (n = 7).
Control biopsies were taken from living donor derived grafts before implantation (n = 10).
While biopsies from patients with borderline or AR where taken on average 3.8 and 5.3, biop-
sies from kidneys with IFTA were taken on average 73.5 months post-transplant (range 12–
180 m) (Table 2). Detailed histopathological changes in each group are shown in Fig 3A. As
expected, acute tubulointerstitial inflammation was significantly more pronounced in border-
line and AR compared to the IFTA group. On the other hand chronic tubulointerstitial inflam-
mation and chronic glomerulitis (transplant glomerulopathy) were significantly stronger in
the IFTA group compared to AR and BR. Acute arteriitis was only present in AR, but not in
borderline rejection or IFTA (Fig 3B).
As illustrated in Fig 3C, both, biopsies with borderline lesions and AR, demonstrated signif-
icant induction of LTα and LTβ mRNA. Interestingly, we observed no expression differences
between borderline lesions and biopsies with AR. Biopsies from kidneys with IFTA demon-
strated significantly less LTβ mRNA expression compared to biopsies with AR. The mRNA
expression of LTβR did not demonstrate significant regulation, even though LTβR was promi-
nently expressed (with Ct values between 23 and 29). However as observed in the microarray
dataset, LIGHT mRNA was significantly upregulated in acute and borderline rejection,
whereas its receptor HVEM was not. Also the TNF superfamily member DcR3 (TNFSFR6A), a
soluble decoy receptor, which binds to LIGHT, TLA1 and Fas ligand (FasL) [36] displayed
Lymphotoxin in renal allografts
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upregulation in borderline and AR, but not in chronic allograft injury. To assess whether cyto-
kine (receptor) mRNA levels correlated with histopathological changes we performed Spear-
man’s correlation analysis. There was only a moderate correlation between active tubulitis/
interstitial inflammation (atii) and the expression level of Ltβ mRNA (p<0.05) and active
arteritis (av) and the expression of the LTβR mRNA (p<0.05) when patients from all groups
Fig 1. Upregulation of LT and non-canonical NF-κB pathway target transcripts in human renal allograft biopsies
with AR and IFTA. LTβ, TNFRs1 and 2, LIGHT and HVEM mRNA expression in human renal biopsies with AR
(n = 8; A) or chronic allograft nephropathy (n = 21; B) was significantly increased when compared to controls, which
were obtained from nephrectomy specimens after explantation (n = 12). Also, CXCL12, CXCL13, CCL 19 and BAFF
showed significant upregulation in AR (C) and IFTA (D). Displayed are fold changes compared to controls
(nonaffected renal cortex from renal cancer nephrectomy samples). All fold changes shown were statistically
significant compared to controls. ( q-value< 0.05,  q < 0.01,  q< 0.001).
https://doi.org/10.1371/journal.pone.0189396.g001
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were analyzed together (S1 Fig top left). In patients with borderline rejection there was no sig-
nificant correlation between cytokine mRNA and histopathological changes (S1 Fig top right).
In patients with acute rejection (AR) there was a significant negative correlation between atii
and the expression of LTβR mRNA and a positive correlation between the expression of DCR3
mRNA and active glomerulitis (S1 Fig bottom left). Surprisingly, in patients with IFTA we
observed a strong correlation between ctii and LTβ mRNA expression (S1 Fig bottom right).
LTβ is expressed by tubular epithelial cells and infiltrating inflammatory
cells in human renal allograft biopsies with AR and IFTA
To verify expression of LTβ on the cellular level we performed immunohistochemistry using a
monoclonal antibody against human LTβ on paraffin sections from kidney biopsies of 39 kid-
ney transplant patients including ten pre-implant biopsies as controls (S4 Table). LTβ positiv-
ity was mostly confined to mononuclear inflammatory cells. These infiltrates ranged from
Fig 2. Clustered heatmap of the gene set influenced by lymphotoxin from array data. Samples (x-axis) show
transplant glomerulopathy clusters 1 and 2 in comparison to control kidneys. Genes (y-axis) are clustered and colored
based on their relative expression levels. The color scale is a double gradient, green is very low expression, average
expression is dark and higher expressions are red.
https://doi.org/10.1371/journal.pone.0189396.g002
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Fig 3. Upregulation of LT mRNAs in human renal allograft biopsies. (A) Detailed pathological changes of ERCB
renal biopsy specimens in the different groups: BR (n = 10), AR (n = 22) and chronic injury (IFTA) (n = 7); atii acute
tubulointerstitial inflammation, ctii chronic tubulointerstitial inflammation/interstitial fibrosis tubular atrophy, ag
acute glomerulitis, cg chronic glomerulitis/transplant glomerulopathy, av acute intimal arteritis, cv chronic intimal
arteritis/ arterial fibrous intimal thickening, mm mesangial matrix increase. BR borderline rejection, AR acute
rejection, IFTA interstitial fibrosis/tubular atrophy. Displayed are mean score + SEM. (B) Displays significant
differences between groups. (C) LTα, LTβ, LTβ receptor, DcR3 and LIGHT mRNA expression was quantified by
quantitative RT-PCR (). Control biopsies were taken from living donors (LD) before implantation (n = 10). Significant
upregulation is shown for Ltα, LTβ, DcR3 and LIGHT in borderline and AR. No differential regulation was observed
Lymphotoxin in renal allografts
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diffuse accumulations in the tubulointerstitium to inflammatory cell aggregates with follicular
appearance. Morphologically, the majority of positively stained cells resembled lymphocytes.
In addition to infiltrating cells, we often observed strong immunoreactivity in the cytoplasm of
tubular epithelial cells. Sometimes only one isolated cell within a tubular cross-section was
positive, but at times also the entire tubular cross-section. (Fig 4). In the semiquantitative anal-
ysis, LTβ positivity in tubular epithelial cells was significantly more frequent in AR and IFTA
compared to controls. Follicular infiltrates with Ltβ positivity were more frequent in AR com-
pared to controls, whereas diffuse infiltrates with LTβ positivity were significantly more fre-
quent in both AR and IFTA when compared to control biopsies. We did not observe a clear
difference between biopsies with AR and biopsies with IFTA. In the implant biopsies, there
was barely any immunoreactivity for LTβ (Fig 4).
mRNAs of the lymphotoxin family are strongly upregulated in rejected
mouse renal allografts
Finally, we investigated the expression of lymphotoxins in renal allograft rejection in a murine
model. We transplanted kidneys from C57BL/6 mice into CBA (fully MHC mismatched allo-
grafts) or into C57BL/6 (isografts). Endogenous kidneys were used as controls. Kidneys were
removed after seven days without any immunosuppressive treatment. Fig 5 illustrates results
of the mRNA expression analysis of the lymphotoxin system. A highly significant induction
was found for LTα, LTβ, HVEM and LIGHT, but again no change in expression was detected
for the LTβ receptor mRNA. These data are consistent with our expression analysis from
human kidneys, where also no regulation was found for the LTβ receptor.
Discussion
Since LTs have an important function in various inflammatory processes we investigated the
expression of members of the LT family and LT target genes in acute and chronic allograft
injury. Analysis of transcriptomes from kidney grafts demonstrated robust upregulation of
LTβ, LIGHT and one of its receptors, HVEM, as well as TNF receptors 1 and 2 mRNA in AR
(Fig 1A). Interestingly, in chronic allograft injury/IFTA we observed a similar pattern (Fig 1B).
The upregulation of transcripts controlled by the NF-κB signalling pathway, such as CXCL12
(SDF-1), CXCL13 (BLC), CCL19 (ELC) and BAFF in AR and IFTA (Fig 1C and 1D) strongly
suggests activation of the LTα1β2-LTβR or LIGHT-LTβR axis since aside from CD40L-CD40
interaction and BAFF [37–40] LTβR activation is one of three major inducers of the alternate
NF-κB pathway [41]. CD40L was neither upregulated in AR nor chronic allograft nephropathy
and therefore is unlikely to be solely responsible for the assumed alternate NF-κB pathway
triggering in this context. Because BAFF expression itself can be induced upon LTβR ligation
via non-canonical NF-κB activation [20], it is difficult to dissect whether BAFF upregulation
was a consequence or cause of the presumed activation of the alternate NF-κB pathway. LTα
and TNFα mRNAs were not significantly increased in the transcriptome of grafts with AR and
IFTA compared to nephrectomy controls which was unexpected, since lymphocytes as well as
resident dendritic cells have been shown to express these cytokines [42–44]. LTβR mRNA did
not show any differential regulation. This is in line with the previously described constitutive
expression of the receptor in parenchymal cells and its promotor region suggesting a house
for HVEM and the LTβR. There was a tendency towards higher expression of Ltα, LTβ, DcR3 and LIGHT mRNA in
IFTA compared to controls, however results did not reach significance. The graphs show expression ratios of each gene
normalized to 18 srRNA ( p< 0.05; p< 0.01,  p<0.001.
https://doi.org/10.1371/journal.pone.0189396.g003
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keeping function [45]. Also earlier studies from our group in patients with various forms of
glomerulonephritis, demonstrated that LTβR expression was unaltered in inflamed kidneys
[15].
In a second experimental paradigm, mRNA expression patterns of members of the LT fam-
ily and structurally related genes were assessed using cDNA arrays in patients with another
chronic renal allograft injury, transplant glomerulopathy. Clustering analysis of mRNA
expression from the tubulointerstitial compartment showed two distinct expression patterns.
One cluster displayed strong upregulation of LTα, TNF, LIGHT, HVEM, BTLA, CXCL13,
CCR7 and CCL21 (cluster 1), whereas the second pattern (cluster 2) was characterized by
increased expression of the LTβR, LTβ, TNF receptors 1 and 2, MADCAM and TROY (Fig 2).
The segregation of these two clusters could reflect different progression stages of transplant
glomerulopathy or alternatively distinctive underlying pathologies characterized by engage-
ment of a different subset of components of the LT and TNF system ultimately resulting in a
similar histopathologic pattern. The clusters could also reflect different stages of chronic inter-
stitial inflammation with formation of ectopic lymphoid follicles. Thaunat and others per-
formed similar experiments in explanted renal allografts with terminal graft failure due to
chronic rejection. They investigated the expression of several transcripts involved in ectopic
lymphoid neogenesis such as LTα, β, LTβR, CXCL12, 13, CXCR4, 5, CCL19, 21 and CCR7. By
hierarchical clustering, they identified three different clusters, which they attributed to differ-
ent stages of lymphoid neogenesis in the allograft [46].
Other groups have shown expression of LTα in acutely rejecting kidney grafts [26, 47].
Using cDNA from the ERCB-KFB, we confirmed these findings and also detected robust upre-
gulation of LTβ, and LIGHT in borderline rejection and AR when compared to controls from
kidney biopsies of living donors before implantation (Fig 3). In allografts with IFTA we also
Fig 4. Semiquantitative expression of LTβ in human allograft biopsies. LTβ immunohistochemistry was performed
in biopsies with acute rejection (AR), IFTA (IFTA) and controls (ctrl). Upper panel shows semiquantitative analysis of
LTβ positivity in tubular epithelial cells (TECs; left), LTβ positivity in infiltrating inflammatory cells in follicular
infiltrates (middle) and LTβ positivity in diffusely infiltrating inflammatory cells (right). The lower panel shows
examples of LTβ positivity in TECs (left; arrow depicts positively stained tubular epithelial cell), follicular infiltrates
(middle; arrow depicts follicular infiltrate) and diffusely infiltrating cells (right) (scale bar = 50 μM;  p< 0.05; 
p< 0.01,  p< 0.001).
https://doi.org/10.1371/journal.pone.0189396.g004
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noticed a trend towards higher expression of LTα, β and LIGHT, which, however, did not
reach statistical significance (Fig 3). In line with the above findings, LTβR was again not differ-
entially regulated. Interestingly, also the decoy receptor 3 (DcR3 /TNFRSF6B) message was
significantly upregulated in AR. DcR3 is a secreted decoy receptor which binds to and blocks
the biologic action of the ligands FasL and LIGHT [36, 48–50] but can also activate T cells via
binding to TL1A [51]. It has recently been demonstrated to have negative prognostic value in
CKD and HD patients [52]. Whether DcR3 is also a predictor of negative outcome in renal
transplant patients needs to be determined. Interestingly, there was not a significant expression
difference between borderline and AR with respect to the transcripts investigated. This could
indicate that despite a morphologic difference on the light microscopic level acute and border-
line rejection share features on the transcriptional level. Another explanation, which has been
pointed out before, is that the Banff histological criteria are unreliable at the interface between
Fig 5. Quantification of lymphotoxin mRNAs in mouse renal allografts. Mean fold-induction of LTα, LTβ, LTβ
receptor (all upper panel), HVEM and LIGHT mRNAs (lower panel) quantified by quantitative RT-PCR,
demonstrated for full mismatched allografts (AG) compared to isografts (IG) (control) seven days post transplantation.
A very significant induction was found for LTα, LTβ, HVEM, LIGHT, but no regulation was found for the LTβ
receptor. ( p< 0.05,  p< 0.01,  p<0.001, ns = non significant.)
https://doi.org/10.1371/journal.pone.0189396.g005
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borderline and acute rejection. Therefore, some of the cases diagnosed with borderline rejec-
tion might in fact have been cases of acute rejection [53,54].
In our study, most of the cytokine (receptor) mRNA levels in the different subgroups (bor-
derline, AR and IFTA) did not significantly correlate with the degree of histopathological
changes in the different renal compartments (S1 Fig). This does not indicate that the expres-
sion changes are insignificant. Several studies have shown that transcriptional upregulation of
inflammatory genes or genes associated with injury do not correlate well with morphological
changes in transplant biopsies, but often predict the outcome better than the histology [55,
56]. We cannot of course completely exclude that the lack of correlation is of methodological
nature, since we extracted the histopathological changes from the biopsy reports and could not
evaluate the changes directly from the histology slides.
To investigate the expression of LTβ on the protein level, we performed immunohis-
tochemistry with an LTβ specific antibody. The analysis exhibited LTβ immunoreactivity in
inflammatory cells and tubular epithelial cells in biopsies with AR and IFTA. In implant biop-
sies, we rarely observed LTβ immunoreactivity (Fig 4). In a previous study, we have also
observed LTβ expression in TECs in biopsies from kidneys with different forms of glomerulo-
nephritis [15]. The observed upregulation of LTβ in TECs suggests that tubular damage or
TEC activation by cytokines from infiltrating cells leads to upregulation and release of LTβ by
TECs, which may activate the LTβR on neighboring TECs and/or local immune cells such as
DCs, modulating the inflammatory response. That TECs serve as regulatory cells in acute
rejection—either amplifying or ameliorating inflammation—has been shown in previous stud-
ies [57]. Interestingly, we did not observe tubular expression of LTβ in implant biopsies. This
indicates that even a severe ischemic stimulus (several hours of cold and minutes of warm
ischemia) does not suffice to induce LTβ expression in TECs. As in kidneys with various forms
of glomerulonephritis [15], expression of LTβ was observed in infiltrating mononuclear
inflammatory cells diffusely within the tissue or in follicular or follicular-like infiltrates.
To investigate the expression of LTs in renal transplants in another species we employed an
intrinsically very homogeneous model of acute renal allograft rejection using two fully mis-
matched inbred mouse strains [33]. In this model system, we were able to recapitulate our
findings from human biopsy studies. Seven days after orthotopic renal grafting without immu-
nosuppressive treatment histology of allografts showed severe acute tubulointerstitial rejection
with interstitial edema, inflammatory infiltrates, tubulitis and signs of acute tubular injury.
qPCR displayed significant induction of LTα, LTβ, HVEM and LIGHT mRNAs. Again LTβR
was not differentially expressed (Fig 5). Whereas LTα has been detected in rat kidney trans-
plants [25], to our knowledge, our study is the first showing upregulation of members of the
LT family in rejected mouse kidney allografts. These findings indicate—at least with respect to
the LT system—that mice react in a similar fashion than humans to engraftment with a foreign
kidney. Given the ample disparities between the human and mouse immune system, this find-
ing is critical regarding the translatability of results from studies in renal transplantation using
this model system.
There are limitations to this study. We did not perform immunohistochemistry for LIGHT,
LTα and HVEM, because in our experience, it is unreliable on archival paraffin embedded
material. Therefore, apart from LTβ the observed changes were documented on the transcrip-
tional level and we cannot make a statement in which renal compartment the expression
changes occurred. It is likely, that at least part of the differential expression of the investigated
transcripts was due to infiltrating cells. Why LTα mRNA was significantly upregulated in AR
in the transcriptional analysis of the ERCB but not the GEO cohort is unclear. The fact that
LTα was upregulated so strongly in AR and BR in the ERCB cohort, however, suggests that the
findings are not coincidental. Finally, whether and which components of the LT system serve
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as positive or negative regulators in graft rejection cannot be deduced from our data and needs
to be determined in future studies. Interfering with the LT system could be beneficial or coun-
terproductive in solid organ transplantation. In a murine model of heart transplantation,
blockade of LIGHT signaling lead to significantly prolonged graft survival [58]. Conversely,
LTβR blockade in another model broke tolerance and caused inflammation and fibrosis in the
cardiac allograft [59]. These equivocal results might relate to the fact that the network of inter-
actions in the LT system is particularly complex as ligands can interact with different receptors
and vice versa, making it difficult to anticipate the net effect of an intervention. In addition,
manipulation of the LT system might not only result in blockade of specific processes such as
inhibition of costimulation in T cell activation via LIGHT-HVEM but possibly also in global
perturbance of immune effector functions as a consequence of secondary lymphoid organ dis-
ruption [13, 59].
To summarize, our results demonstrate that essentially all components of the LT system are
expressed in human renal allografts with acute rejection and chronic injury as well as in acutely
rejected mouse allografts. Furthermore, a subset of them are strongly upregulated in acute and
chronic allograft injury. We therefore provide evidence for the involvement of the LT system
in acute kidney rejection and chronic allograft injury. Yet, the exact functional and possibly
diagnostic role of the LT system in these processes awaits further studies.
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